These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

554 related items for PubMed ID: 26343583

  • 1. Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.
    Peng SB, Henry JR, Kaufman MD, Lu WP, Smith BD, Vogeti S, Rutkoski TJ, Wise S, Chun L, Zhang Y, Van Horn RD, Yin T, Zhang X, Yadav V, Chen SH, Gong X, Ma X, Webster Y, Buchanan S, Mochalkin I, Huber L, Kays L, Donoho GP, Walgren J, McCann D, Patel P, Conti I, Plowman GD, Starling JJ, Flynn DL.
    Cancer Cell; 2015 Sep 14; 28(3):384-98. PubMed ID: 26343583
    [Abstract] [Full Text] [Related]

  • 2. LY3009120, a panRAF inhibitor, has significant anti-tumor activity in BRAF and KRAS mutant preclinical models of colorectal cancer.
    Vakana E, Pratt S, Blosser W, Dowless M, Simpson N, Yuan XJ, Jaken S, Manro J, Stephens J, Zhang Y, Huber L, Peng SB, Stancato LF.
    Oncotarget; 2017 Feb 07; 8(6):9251-9266. PubMed ID: 27999210
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Oncogenic BRAF Deletions That Function as Homodimers and Are Sensitive to Inhibition by RAF Dimer Inhibitor LY3009120.
    Chen SH, Zhang Y, Van Horn RD, Yin T, Buchanan S, Yadav V, Mochalkin I, Wong SS, Yue YG, Huber L, Conti I, Henry JR, Starling JJ, Plowman GD, Peng SB.
    Cancer Discov; 2016 Mar 07; 6(3):300-15. PubMed ID: 26732095
    [Abstract] [Full Text] [Related]

  • 6. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.
    Poulikakos PI, Zhang C, Bollag G, Shokat KM, Rosen N.
    Nature; 2010 Mar 18; 464(7287):427-30. PubMed ID: 20179705
    [Abstract] [Full Text] [Related]

  • 7. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R.
    Pharmacol Res; 2018 Sep 18; 135():239-258. PubMed ID: 30118796
    [Abstract] [Full Text] [Related]

  • 8. Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation.
    Miyauchi S, Shien K, Takeda T, Araki K, Nakata K, Miura A, Takahashi Y, Kurihara E, Ogoshi Y, Namba K, Suzawa K, Yamamoto H, Okazaki M, Soh J, Tomida S, Yamane M, Sakaguchi M, Toyooka S.
    Anticancer Res; 2020 May 18; 40(5):2667-2673. PubMed ID: 32366411
    [Abstract] [Full Text] [Related]

  • 9. Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.
    Mooz J, Oberoi-Khanuja TK, Harms GS, Wang W, Jaiswal BS, Seshagiri S, Tikkanen R, Rajalingam K.
    Sci Signal; 2014 Aug 05; 7(337):ra73. PubMed ID: 25097033
    [Abstract] [Full Text] [Related]

  • 10. Optogenetically controlled RAF to characterize BRAF and CRAF protein kinase inhibitors.
    Chatelle CV, Hövermann D, Müller A, Wagner HJ, Weber W, Radziwill G.
    Sci Rep; 2016 Mar 30; 6():23713. PubMed ID: 27025703
    [Abstract] [Full Text] [Related]

  • 11. LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
    Monaco KA, Delach S, Yuan J, Mishina Y, Fordjour P, Labrot E, McKay D, Guo R, Higgins S, Wang HQ, Liang J, Bui K, Green J, Aspesi P, Ambrose J, Mapa F, Griner L, Jaskelioff M, Fuller J, Crawford K, Pardee G, Widger S, Hammerman PS, Engelman JA, Stuart DD, Cooke VG, Caponigro G.
    Clin Cancer Res; 2021 Apr 01; 27(7):2061-2073. PubMed ID: 33355204
    [Abstract] [Full Text] [Related]

  • 12. Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.
    Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, Galvin K, Okaniwa M, Ishikawa T, Yoshida S.
    Cancer Res; 2013 Dec 01; 73(23):7043-55. PubMed ID: 24121489
    [Abstract] [Full Text] [Related]

  • 13. Discovery of a novel pan-RAF inhibitor with potent anti-tumor activity in preclinical models of BRAFV600E mutant cancer.
    Hong SP, Ahn SK.
    Life Sci; 2017 Aug 15; 183():37-44. PubMed ID: 28645859
    [Abstract] [Full Text] [Related]

  • 14. ARAF acts as a scaffold to stabilize BRAF:CRAF heterodimers.
    Rebocho AP, Marais R.
    Oncogene; 2013 Jun 27; 32(26):3207-12. PubMed ID: 22926515
    [Abstract] [Full Text] [Related]

  • 15. CRAF dimerization with ARAF regulates KRAS-driven tumor growth.
    Venkatanarayan A, Liang J, Yen I, Shanahan F, Haley B, Phu L, Verschueren E, Hinkle TB, Kan D, Segal E, Long JE, Lima T, Liau NPD, Sudhamsu J, Li J, Klijn C, Piskol R, Junttila MR, Shaw AS, Merchant M, Chang MT, Kirkpatrick DS, Malek S.
    Cell Rep; 2022 Feb 08; 38(6):110351. PubMed ID: 35139374
    [Abstract] [Full Text] [Related]

  • 16. Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation.
    Su F, Bradley WD, Wang Q, Yang H, Xu L, Higgins B, Kolinsky K, Packman K, Kim MJ, Trunzer K, Lee RJ, Schostack K, Carter J, Albert T, Germer S, Rosinski J, Martin M, Simcox ME, Lestini B, Heimbrook D, Bollag G.
    Cancer Res; 2012 Feb 15; 72(4):969-78. PubMed ID: 22205714
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition.
    Yao Z, Torres NM, Tao A, Gao Y, Luo L, Li Q, de Stanchina E, Abdel-Wahab O, Solit DB, Poulikakos PI, Rosen N.
    Cancer Cell; 2015 Sep 14; 28(3):370-83. PubMed ID: 26343582
    [Abstract] [Full Text] [Related]

  • 19. Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
    Shao W, Mishina YM, Feng Y, Caponigro G, Cooke VG, Rivera S, Wang Y, Shen F, Korn JM, Mathews Griner LA, Nishiguchi G, Rico A, Tellew J, Haling JR, Aversa R, Polyakov V, Zang R, Hekmat-Nejad M, Amiri P, Singh M, Keen N, Dillon MP, Lees E, Ramurthy S, Sellers WR, Stuart DD.
    Cancer Res; 2018 Mar 15; 78(6):1537-1548. PubMed ID: 29343524
    [Abstract] [Full Text] [Related]

  • 20. LY3009120, a pan-Raf kinase inhibitor, inhibits adipogenesis of 3T3-L1 cells by controlling the expression and phosphorylation of C/EBP-α, PPAR-γ, STAT‑3, FAS, ACC, perilipin A, and AMPK.
    Yang SM, Park YK, Kim JI, Lee YH, Lee TY, Jang BC.
    Int J Mol Med; 2018 Dec 15; 42(6):3477-3484. PubMed ID: 30272260
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.